Uncategorized
Novartis’ RTH258 for wet AMD meets endpoints in phase 3 trials
RTH258 for wet age-related macular degeneration met its primary and key secondary endpoints in two phase 3 studies, according to a Novartis press release.The HAWK and HARRIER trials studied the non-inferiority of RTH258 (brolucizumab, 6 mg) vs. Eylea (aflibercept, Regeneron) in regards to change in best corrected visual acuity from baseline to week 48 and average mean change between week 36 and week 48. These endpoints were met with significant P values.